Product Specifications Compound: CJC-1295 with DAC Class: Synthetic GHRH analog with albumin-binding modification Origin: Modified GHRH (1-29) analog with N-terminal Drug Affinity Complex Molecular Weight: ~3647 Da Form: Lyophilized powder Vial Size: 5mg in 3mL glass vial Purity: 99%+ verified by HPLC and mass spectrometry (See COAs) Research Background CJC-1295 with DAC has been investigated in research literature across several scientific contexts: GHRH receptor pharmacology investigations into receptor binding kinetics, signal transduction, and cellular response mechanisms in pituitary cell models Albumin-binding peptide research studies examining how covalent serum albumin binding via maleimidopropionic acid modification affects peptide half-life, distribution, and stability properties Peptide half-life engineering analytical chemistry research on extended-duration peptide analogs and the structural modifications that enable prolonged biological activity Comparative GHRH analog research studies positioning CJC-1295 with DAC alongside other modified GHRH peptides (including Sermorelin and Tesamorelin) in cellular research contexts Structure-activity relationships peptide chemistry research on how DAC modification affects receptor binding affinity compared to non-modified GHRH analogs Cellular signaling pathway research investigations into GHRH receptor activation and downstream cellular signaling cascades CJC-1295 with DAC was originally developed by ConjuChem Biotechnologies as part of their broader Drug Affinity Complex peptide research platform, which utilized albumin-binding chemistry to extend peptide half-life across multiple research compound development programs
The treatment strengthens the immune system, helping the body combat infections and inflammation, with many clients reporting increased energy and sharper cognitive function after sessions
10.1016/j.biopha.2022.113705 17 apcA.HerrmannL.Sampath KumarH
Delivery of gene addition therapies may be ex vivo or in vivo depending on the target cell type
However, the amino group of taurine can neutralize hypochlorous acid, one of the reactive species generated by myeloperoxidase-halide system in neutrophils [102]
As newly identified metal ion-dependent programmed cell death modalities, ferroptosis and cuproptosis play critical roles in tumor metabolism, immune microenvironment remodeling, and therapeutic resistance, representing emerging research foci in OSCC
